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Elevated circulating fatty acids are associated with impaired insulin action and inflammation. During
intracellular transit, fatty acids use fatty acid-binding proteins (FABPs) as shuttles. A recent study
(Furuhashi et al., 2007) explores inhibiting FABP4/aP2 as a strategy for treating atherosclerosis
and type 2 diabetes.Impaired insulin action at its target
tissues, a phenomenon termed insulin
resistance, is typical in obesity, type 2
diabetes, and associated atheroscle-
rosis but also occurs during inflamma-
tory and neoplastic processes. The
development of insulin resistance has
been linked to augmented availability
of lipids and other nutrients. Specifi-
cally, plasma concentrations of free
fatty acids (FFAs) are elevated in insu-
lin resistance and even predict type
2 diabetes (Roden, 2006). Over past
years, evidence has accumulated
that FFAs induce insulin resistance by
raising intracellular lipid metabolites,
which, in turn, activate protein kinase
C, inhibitor of nuclear factor kappa
B kinase (IKK) and c-jun N-terminal
kinase (JNK), leading to serine phos-
phorylation and subsequent inhibition
of insulin receptor substrates (Lowell
and Shulman, 2005; Roden, 2006).
The concentrations of FFAs can in-
crease either in the circulating blood
due to high-fat diet and release by ad-
ipocytes or within cells consequent
to lipolysis or de novo synthesis. FFAs
tour through the body mainly while
bound to fatty acid transport proteins,
whereas fatty acid-binding proteins
(FABPs) regulate their intracellular fate
(Figure 1). Specifically, the adipocyte-
specific isoform (FABP4, A-FABP, or
aP2) has gained attention for its pro-
posed role in metabolic disorders and
atherosclerosis. Althoughmice lacking
FABP4 (aP2/) exhibit an unremark-
able metabolic phenotype at baseline
(explained by upregulation of another
FABP isoform, mal1), they were pro-
tected from dietary-induced insulinresistance despite increased body
weight and plasma FFAs (Hotamisligil
et al., 1996). Moreover, macrophage-
specific aP2 knockout prevents ath-
erosclerotic lesions in Apo-E knockout
mice (apoe/) on a high-cholesterol
Western diet, a murine model of ath-
erosclerosis (Makowski et al., 2001).
Taken along with the observation of
accelerated cholesterol storage in
aP2-overexpressing macrophages
(Fu et al., 2006), these data suggest
that aP2 could be an attractive target
for treating insulin resistance and
atherosclerosis.
Hotamisligil and colleagues tested
whether pharmacological inhibition of
FABP4/aP2 reduces inflammatory
pathway signaling and insulin resis-
tance in mouse models of atheroscle-
rosis, obesity, and diabetes mellitus
(Furuhashi et al., 2007). They used an
aromatic biphenyl azol compound,
BMS309403, a competitive inhibitor
of FFA binding to FABP4/aP2 which
carries the distinct advantages of tar-
get specificity and oral availability.
BMS309403 was administered to
apoe/ mice fed a Western diet, ei-
ther at the start (early intervention) or
after 8 weeks (late intervention) of the
diet. After 6 weeks, treated animals
had50% less atherosclerotic lesions
in the aorta compared to a vehicle-
treated group, whereas body weight,
glucose metabolism, and lipid metab-
olism were not different. In this model,
atherosclerotic lesions show ‘‘fatty
streaks’’ consisting mostly of macro-
phage-derived foam cells. In vitro, the
FABP4/aP2 inhibitor diminished mac-
rophage transformation into foam cellsCell Metabolisas indicated by 40% reduction of
cholesterol ester accumulation, which
was primarily attributed to a doubling
of cholesterol export. In addition, treat-
ment with BMS309403 lessened the
release of cytokines such asmonocyte
chemoattractant protein (MCP-1/
CCL2), interleukins (IL-1b, IL-6), and
tumor necrosis factor (TNF). Of note,
none of these effects were observed
in aP2/ cells, indicating a specific re-
quirement for FABP4/aP2 for foam cell
generation and cytokine release.
The authors then testedBMS309403
inmodels of genetic and acquired obe-
sity. After 6 weeks of treatment, leptin-
deficient ob/ob mice (Lepob/ob) pre-
sented with lower circulating glucose,
insulin, and triglycerides as well as
higher adiponectin levels, which are
all in linewith improved insulin sensitiv-
ity and glucose tolerance. Of note,
plasma glucose also fell when the
FABP4/aP2 inhibitor was administered
in wild-type, but not in FABP-deficient,
mice on a high-fat diet. FABP4/aP2
inhibition did not affect pancreatic islet
morphology but did result in doubling
of glucose infusion rates during hyper-
insulinemic-euglycemic clamp stud-
ies. This was due to suppression of
endogenous (hepatic) glucose produc-
tion and increased glucose uptake in
skeletal muscle and adipose tissue.
Treated Lepob/obmice further exhibited
a lower degree of macrophage infiltra-
tion and expression of chemoattrac-
tant and inflammatory cytokines in
adipose tissue. Their livers contained
30% less triglycerides along with
diminished expression of lipogenic en-
zymes. In both liver andadipose tissue,m 6, August 2007 ª2007 Elsevier Inc. 89
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PreviewsFigure 1. Fatty Acids’ Tour through the Body
Free fatty acids (FFAs) bind to FABP4/aP2, with activation (red plus signs) of numerous intracellular pathways in small adipocytes and macrophages.
This leads to differentiation of small adipocytes into large adipocytes, which store more triglycerides but also release FFAs and adipokines, including
tumor necrosis factor (TNF) and interleukins (IL). These factors contribute to the development of insulin resistance in hepatocytes andmyocytes. Upon
FFA-FABP4/aP2 activation, macrophages differentiate into foam cells, which store cholesterol esters and release cytokines such as TNF, IL, and
monocyte chemoattractant protein (MCP-1). These factors are involved in many steps of atherosclerotic plaque formation, activation (including
increased inflammatory responses), and recruiting monocytes into the atherosclerotic lesion. A small molecule inhibitor of FABP/aP2 (green arrow-
heads) acts as a competitive inhibitor of FFA-FAPB4/aP2 binding and interferes with the above processes (green minus signs), thereby preventing
both insulin resistance and atherosclerosis in vivo and in vitro.FABP4/aP2 inhibition reduced the ac-
tivity of the mediator of cellular inflam-
mation, JNK1, by40%and increased
insulin signal transduction.
While this study offers convincing
arguments for FABP4/aP2 inhibition
as a therapeutic principle, some ques-
tions arise. First, what is the physiolog-
ical function of FABP4 and what is the
long-run consequence of its impair-
ment? In addition to FFAs, other lipid
metabolites and insulin regulate
FABP4, possibly ensuring sufficient
lipid storage in adipocytes and intact
inflammatory/immune responses in
macrophages. These functions of
FABP4 might have been life saving
for our ancestors and could still be
useful for contemporary humans. Even
if no effects of FABP4/aP2 inhibition
were noted under basal conditions,
one would like to know the impact of
the inhibitor on long-term body weight
regulation and under conditions re-
quiring strong immune and inflamma-
tory responses. Second, what are the
possible consequences of the slight
but consistent increase in circulating
FFAs observed during inhibition, re-
ported in Furuhashi et al. (2007), or
knockout of FABP4/aP2? Elevated
FFAs can cause insulin resistance ex-
clusively in skeletal muscle (Lowell90 Cell Metabolism 6, August 2007 ª200and Shulman, 2005), although usually
higher plasma FFA concentrations
than those observed by FABP4/aP2
inhibition are required to induced insu-
lin resistance in rodents and humans.
Moreover, FFAs not only interact with
FABP4 but also stimulate Toll-like re-
ceptor 4 (TLR4) in adipocytes and
macrophages, with cellular and endo-
crine effects almost identical to those
following FABP4 activation. Indeed,
TLR4 knockout mice exhibit partial
protection from lipid- and diet-induced
insulin resistance (Shi et al., 2006). This
raises questions of a hierarchy within
the network of lipid-induced events
in different tissues and of the mutual
compensation if one partner of this
network is blocked or overactivated.
Third, what is the direct cause of im-
proved insulin sensitivity in skeletal
muscle upon FABP4/aP2 inhibition?
Different strains of FABP4/aP2/
mice yielded heterogeneous results,
with either a favorable (increased
short-chain) fatty acid profile and in-
creased AMP kinase or unchanged
fatty acid profiles and minor increases
in adiponectin, but no changes in other
cytokines (Hertzel et al., 2006).
Finally, are these data of relevance
for humans? Recently, some evidence
supporting a role of FABP4 in humans7 Elsevier Inc.has been reported. Carriers of the
T-87C polymorphism at the aP2 pro-
moter present with reduction of aP2
expression in adipose tissue, plasma
triglycerides, and risk for coronary
heart disease, but no alterations of
other metabolic or inflammatory
markers nor risk of diabetes (Tuncman
et al., 2006). Plasma FABP4 concen-
trations further positively correlate
with the number of traits of the meta-
bolic syndrome, body mass, and indi-
ces of insulin resistance in Caucasians
(Stejskal and Karpisek, 2006) as well
as with the adiponectin levels in an
Asian population (Xu et al., 2007). In
the latter case, FABP4 levels even pre-
dict the incidence of the metabolic
syndrome over the course of 5 years,
independent of adiposity and insulin
resistance. This observation raises
further questions on the role of FABP
as a transporter of FFAs during their
tour from adipose tissue to liver and
skeletal muscle and as a novel marker
of cardiometabolic disorders and has
implications for the current paradigm
that obesity and insulin resistance
mainly explain the metabolic syn-
drome.
Taken together, FABP4 clearly links
some mechanisms that are centrally
involved in the joint development of
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Previewsobesity, type 2 diabetes, and athero-
sclerosis. The concept of blocking
FFA binding to this protein is clearly in-
novative, but we will need more infor-
mation on possible side effects before
FABP4 inhibitors can be considered
for treating patients.
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